Ubamatamab not checked

Regeneron · REGN4018

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
5 in total · 3 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Ovarian Cancer (2 trials), Fallopian Tube Cancer (2 trials), Primary Peritoneal Cancer (2 trials), Endometrial Cancer (2 trials), Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung and 5 more
Main trialPhase 2
“This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study…”In the company’s words, NCT06787612 on ClinicalTrials.gov
Other names
REGN4018

Other drugs for Ovarian Cancer

All 265 drugs for Ovarian Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Jun 2028 Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Phase 2Recruiting 10 Jun 2030 A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2Recruiting 10 May 2027 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Phase 1/2Recruiting 8 Nov 2028 A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Phase 1/2Authorised not given REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ubamatamab

Following is part of Solo: you see every change to Ubamatamab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in